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1. Introduction 
Advanced melanoma has the highest per-death loss of years of potential life expectancy 
second only to adult leukemia. The incidence of melanoma continues to rise worldwide at 
approximately 3% per year, and in 2009 there were an estimated 68,720 new cases in the 
United States and 8650 deaths (Balch et al. 2009). According to Surveillance Epidemiology and 
End Results (SEER) data, roughly 4% of melanomas are metastatic at time of diagnosis. Locally 
advanced or recurrent unresectable, and disseminated melanoma is notoriously unresponsive 
to standard treatment, and is associated with a dismal prognosis.  Patients with metastatic 
melanoma have a median survival of 8 months and 2-year survival rates of 10% to 15%. (Tsao 
et al. 2004). Until March of 2011, only 2 drugs were approved by the Food and Drug 
Administration (FDA) in the United States (US) for metastatic melanoma: interleukin 2 (IL-2) 
and dacarbazine (ipilimumab was approved in March of 2011 and will be discussed in this 
chapter).   Dacarbazine is an alkalyting agent that in 1975 became the first chemotherapeutic 
drug approved by the US FDA for metastatic melanoma. Response rates for this regimen were 
20% in a 30-year overview (Serrone et al. 2000), whereas more recent studies showed response 
rates in the 10-14% range (Bedikian et al. 2006; Chapman et al. 1999; Middleton et al. 2000). 
Temozolomide, an orally available congener of dacarbazine, was shown to be non-inferior in 
efficacy in comparison to dacarbazine in a randomized phase III trial (Middleton et al. 2000). 
Temozolomide had a similar objective response rate and overall survival compared to 
dacarbazine, and a significantly longer disease free survival.  IL-2 was approved by the US 
FDA in 1998 for the treatment of metastatic melanoma.  Single agent IL-2, when given in high 
dose intravenous boluses, leads to objective responses in 16% of patients, with complete 
responses in 6% and partial responses in 10%.  Many patients maintained a complete response 
even after 7 years follow-up (Atkins et al. 2000).  The toxicities of high dose IL-2 are 
substantial, including constitutional symptoms (fevers, chills, fatigue), hypotension, renal 
insufficiency, emesis, diarrhea and thrombocytopenia, and up to 2% of mortality is directly 
related to the treatment (Atkins et al. 2000). A systemic review of 41 randomized clinical trials 
including patients receiving various treatment schedules including biochemotherapy did not 
show improved progression-free survival (PFS) or overall survival (OS) (Eigentler et al. 2003). 
More recently, another meta-analysis of 18 trials involving nearly 2,500 patients with 
metastatic melanoma suggested an increase in response rate to biochemotherapy, but overall 
survival was not improved (Ives et al. 2007). Until today, biochemotherapy and combination 
chemotherapy built upon IL-2 and dacarbazine or temozolomide has not shown statistically 
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significant improvement in overall survival and cannot be regarded as standard therapeutic 
options for metastatic melanoma. Thus, more effective treatment modalities are urgently 
needed.   
2. Agents targeting the immune system 
2.1 CTLA-4 
Increasing knowledge of T-cell regulation has uncovered potential immunologic targets for 
the treatment of melanoma. The interaction between antigen-presenting cells (APC) and T 
lymphocytes is crucial for inducing melanoma-specific T-cell responses. In addition to the 
antigen specific interaction between the HLA peptide complex on the APC and the T-cell 
receptor (TCR), several different co-stimulatory and co-inhibitory molecules modulate the T 
cell response.  For instance, the T-cell surface molecule CD28 interacts with the B7 receptor 
on the APC to mediate a co-stimulatory signal (which is necessary in addition to the HLA-
peptide-TCR interaction for efficient priming of the T cell), whereas the T-cell cytotoxic T-
lymphocyte antigen (CTLA)-4 interacts with B7 to downregulate T-cell activation, acting as 
a natural “checkpoint” on the T-cell mediated immunologic response.  Blocking interaction 
between CTLA-4 and B7 can overcome this checkpoint and enhance T-cell-mediated 
antitumor activity.  This can be achieved by an anti-CTLA-4 monoclonal antibody (mAb).  
To date, two fully human anti-CTLA-4 mAb’s have been developed for metastatic 
melanoma: tremelimumab (CP-675,206; Pfizer Inc., New York) and ipilimumab (MDX-010; 
Bristol-Myers, New Jersey).   
In the initial phase I study, tremelimumab was relatively well tolerated and demonstrated 
encouraging clinical activity including several complete responses. However, in a 
randomized phase III study comparing single-agent tremelimumab with either dacarbazine 
or temozolomide in patients with advanced melanoma, tremelimumab failed to 
demonstrate a significant improvement in OS in comparison to standard chemotherapy 
(Ribas 2008). On the other hand, ipilimumab, in a randomized phase III clinical trial 
comparing ipilimumab alone versus gp100 vaccine alone to the combination of ipilimumab 
and gp100 vaccine, resulted in improved OS of nearly four months (median survival 
duration of 10.1 and 10.0 months in the ipilimumab arm and the combined arm, 
respectively, in comparison to 6.4 months in the vaccination alone (HR 0.66; 95% CI = 0.51-
0.87; p = .033 and HR 0.68; 95% CI = 0.55-0.85; p < .001, respectively). A total of 676 HLA-
A*0201–positive patients with unresectable stage III or IV melanoma, whose disease had 
progressed after one or more of the following therapeutic regimens: dacarbazine, 
temozolomide, fotemustine, carboplatin, or interleukin-2, were included in this study.  This 
was the first randomized clinical trial that showed a statistically significant improvement in 
OS for metastatic melanoma (Hodi et al. 2010).  This agent has now received FDA approval 
for use in metastatic melanoma. 
The activity and side-effect profile of anti-CTLA-4 antibodies have several characteristics 
that reflect their immune-mediated mechanism of action.  Objective responses observed in 
patients with metastatic melanoma with either tremelimumab or ipilimumab were seen in 
approximately 7-10% of patients.  Remarkably, as much as 70% of responses were durable 
(Hodi et al. 2010; Ribas 2008). The unique pattern of response to CTLA-4 mAbs such as 
initial apparent progression of disease, even with emergence of new lesions, followed by 
regression and responses over the course of several months to years, has been seen with 
these agents (Hamid 2007).  The recognition of this unusual kinetics of response has led to a 
 
www.intechopen.com
 
Promising Experimental Therapies for Metastatic Melanoma 
 
185 
 
Fig. 1. T-cell response in melanoma: co-stimulatory and co-inhibitory signals.  B7 proteins on 
antigen-presenting cells serve as ligands for both CD28 receptors and CTLA-4 inhibitory 
molecules on T cells.  Upon T-cell receptor binding to antigen presented on MHCs, B7 
proteins expressed on APCs can bind to CD28 or CTLA-4 receptors on T cells depending 
upon the precise expression patterns of the receptors and ligands and on the state of 
activation of the respective cells.  Ligation of B7 to the CTLA-4 receptor results in inhibitory 
signals for T-cell activation and proliferation.  Conversely, ligation of CD28 provides 
stimulatory signals to T cells leading to their activation.  Interaction between PD-1 and PD-
L1 results in inhibitory signals, whereas interaction between CD40 and CD40-L leads to T 
cell activation.  Ag: antigen; CTLA-4: cytotoxic T-lymphocyte antigen 4; PD-1: programmed 
death 1; TCR: T-cell receptor. 
proposal of immune-related response criteria (irRC) when evaluating treatment responses to 
anti-CTLA-4 mAb’s (Wolchok JD 2009) (table 1). Immune related response criteria should 
replace currently accepted Response Evaluation Criteria in Solid Tumors (RECIST) for the 
evaluation of melanoma patients treated with immunotherapy.  Indeed, it is possible that 
clinical efficacy of tremelimumab may have been missed in the phase III clinical trial owing 
to the failure to recognize that immune response criteria are needed for adequate response 
assessment.   
The growing clinical experience with anti–CTLA-4 mAbs also identifies a constellation of 
autoimmune side effects, which have been designated “immune-related adverse events” or 
irAEs (Di Giacomo et al. 2010).  These irAEs, including rash, autoimmune colitis, hepatitis,  
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 RECIST irRC 
New, measurable 
lesions 
(i.e., ≥5 × 5 mm) 
 
New, nonmeasurable 
lesions (i.e., <5 × 5 mm) 
 
Non-index lesions  
 
 
 
CR 
 
 
 
 
PR  
 
 
 
 
 
 
 
 
SD  
 
 
 
 
 
 
 
 
 
 
 
PD  
 
Always represent PD  
 
 
 
Always represent PD  
 
 
Changes contribute to 
defining 
BOR of CR, PR, SD, and PD 
 
Disappearance of all lesions 
in two consecutive 
observations not less than 4 
wk apart 
 
≥50% decrease in SPD of all 
index lesions compared with 
baseline in two observations 
at least 4 wk apart, in absence 
of new lesions or 
unequivocal progression of 
non-index lesions 
 
50% decrease in SPD 
compared with baseline 
cannot be established nor 
25% increase compared with 
nadir, in absence of new 
lesions or unequivocal 
progression of non-index 
lesions 
 
At least 25% increase in SPD 
compared with nadir and/or 
unequivocal progression of 
non-index lesions and/or 
appearance of new lesions (at 
any single time point) 
 
Incorporated into tumor 
burden 
 
 
Do not define progression 
(but preclude irCR) 
 
Contribute to defining irCR 
(complete disappearance 
required) 
 
Disappearance of all lesions 
in two consecutive 
observations not less than 4 
wk apart 
 
≥50% decrease in tumor 
burden compared with 
baseline in two observations 
at least 4 wk apart 
 
 
 
 
50% decrease in tumor 
burden 
compared with baseline 
cannot be established nor 
25% increase compared with 
nadir 
 
 
 
At least 25% increase in 
tumor burden compared 
with nadir (at any single time 
point) in two consecutive 
observations at least 4 wk 
apart 
Table 1. Comparison between RECIST criteria and the irRC.  BOR: best overall response; 
irCR: immune-related complete response; PD: progressive disease; PR: partial response; SD: 
stable disease; SPD: sum of the products of the two largest perpendicular diameters. 
www.intechopen.com
 
Promising Experimental Therapies for Metastatic Melanoma 
 
187 
and less frequently hypophysitis and uveitis tend to be not harmful provided the clinician is 
aware of these unusual side effects, monitors the symptoms adequately, and knows when to 
intervene.  IrAEs are thought to be a result of non-specific or cross-reactive tissue damage 
caused by activated T-cells.  The most commonly reported rash is a macular and papular 
exanthema affecting trunk and extremities, which has been reported in 47–68 % of patients 
(O'Day et al. 2010; Weber et al. 2009; Wolchok et al. 2010).  These dermatologic irAEs are 
generally mild and symptomatic relief is provided by antihistamines, while grade 3/4 
autoimmune dermatitis is successfully treated with slowly tapered corticosteroids.  At our 
institution, we reported the unique occurrence of hair depigmentation following therapy 
with CTLA-4 monoclonal antibody that correlated with durable clinical responses (figure 2).  
Six of 43 patients developed sudden hair depigmentation starting with the eyebrows, and 
continued to have either complete depigmentation of all body hair or the development of 
diffuse vitiligo.  The median time to depigmentation was 10 months.  All of these patients 
achieved partial response or complete response that sustained during the follow-up period 
of  24-36 months (Pavlick 2010).  
 
 
Fig. 2. Progressive hair depigmentation due to ipilimumab over 3-month period. These 
photographs are published with patient’s permission. 
Diarrhea due to immune-mediated colitis is the most frequent gastrointestinal irAE; if 
untreated, it may lead to serious complications such as intestinal perforation (<1%) (Beck 
et al. 2006). Although grade 3–4 diarrhea is generally reversible with standard anti-
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inflammatory therapies, experience suggests that patients with colitis treated with high-
dose corticosteroids combined with mesalamine, and with seeming resolution of the 
adverse effects, can have an early recrudescence of the symptoms requiring either 
prolonged corticosteroid administration, tumor necrosis factor (TNF) blockade with 
infliximab, or prolonged bowel rest with total parenteral hyperalimentation (Yang et al. 
2007).  Other irAEs such as hepatitis, iridocyclitis and endocrinopathies including 
hypophyisitis, hypothyroidism and adrenal insufficiency are uncommon but worth 
mentioning.  Hepatitis generally presents as asymptomatic rise in the levels of alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST).  In most cases, a delayed 
schedule of anti-CTLA 4 mAb leads to normalization of these levels.  However, unlike 
other irAEs, hypophysitis, which occurs in 1.5% of patients treated with ipilimumab 
(Hodi et al. 2010) often does not improve with high-dose corticosteroids, and permanent 
hormone replacement therapy is required.  Similarly the frequency of hypothyroidism 
and adrenal insufficiency is 1.5% each (Hodi et al. 2010).  Interestingly, development and 
increasing severity of irAEs generally associate with tumor regression and with a 
prolonged time to relapse; nevertheless, this association is not absolute and patients 
without evidence of irAEs have also experienced significant clinical responses (Downey et 
al. 2007; Kahler and Hauschild 2010).   
Melanoma is notorious for its propensity to metastasize to the brain.  Up to 75% of patients 
develop this complication in autopsy series (de la Monte et al. 1983; Patel et al. 1978), and at 
least one third to one half of patients in clinical practice are found to have one or more brain 
metastases during the clinical course of their metastatic disease (Amer et al. 1978; Sampson 
et al. 1998).  Brain metastasis portends a grave prognosis.  The currently available treatment 
options for brain metastasis from melanoma include surgical and radiation therapies which 
may improve the outcome of selected patients with brain metastasis. The most favorable 
outcomes have been reported in patients who are candidates for stereotactic radiosurgery 
(Fife et al. 2004). Even though systemic treatment using cytotoxic agents, such as 
temozolomide in the US, often is employed in the setting of brain metastasis by virtue of the 
ability of temozolomide to cross the blood-brain barrier, its impact on overall survival 
remains unproven (Agarwala et al. 2004; Antonadou et al. 2002; Hwu et al. 2005).  Up to 
date, no single treatment modality has been systematically tested in a randomized clinical 
trial to demonstrate an impact on disease-specific survival.  Encouragingly, treatment with 
CTLA-4 mAb has resulted in durable control of brain metastases (Hodi et al. 2008b; 
Margolin et al. 2010; Schartz et al. 2010). While the phase III trials with ipilimumab excluded 
patients with prior or current brain metastasis, a parallel expanded access trial of 
ipilimumab enrolled patients who were later found to have small brain metastases that had 
not been treated with radiation.  Among those patients, several were noted to have tumor 
regression in the brain. This unexpected observation led to a clinical trial initiated by the 
Cytokine Working Group specifically designed for melanoma patients with one or more 
brain metastases that did not require immediate surgery or radiotherapy. In this trial, 
patients were candidates for ipilimumab therapy if they had no systemic disease, untreated 
disease, or were no longer responding to a prior regimen for systemic disease. Brain 
metastases and extracranial disease were assessed separately, using standard criteria for 
tumor assessment based on the World Health Organization system and a composite global 
response status. The results of this trial, reported at the 2010 ASCO meeting, were 
encouraging. At week 12, for brain alone, the disease control rate was 21.5% (5 of 51 patients 
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achieved partial response, and 6 of 51 patients achieved stable disease); the duration of brain 
disease control ranged from 3 to 15 months (Lawrence 2010). 
2.2 PD-1 
The programmed death 1 (PD-1) receptor is a negative regulator of antigen-activated T cells 
(Fourcade et al. 2009).  It bears homology to CTLA-4 but provides distinct co-inhibitory 
signals. The cytoplasmic domain of PD-1 contains 2 tyrosine signaling motifs that can 
attenuate the TCR/CD28 signal (Parry et al. 2005).  There are two known ligands for PD1: 
B7-H1/PD-L1 (hereafter PD-L1), the predominant mediator of PD-1–dependent 
immunosuppression, and B7-DC/PD-L2. PD-L1 is expressed by many tumors including 
melanoma, and its interaction with PD-1 resulted in tumor escape in experimental models 
(Iwai et al. 2002).  Blockade of the PD-1: PD-L1 pathway in combination with prolonged 
antigen stimulation with melanoma cells augments the number of cytokine-producing, 
proliferating, and total NY-ESO-1-specific CD8 +T cells.  In murine tumor models, the 
inhibition of PD-1: PD-L1 interactions was shown to reverse the generation of functional 
anergy and exhaustion in CD 8+ T cells (Chikuma et al. 2009), and to restore a considerable 
proportion of the effector activity of CD8+ T cells (Blank et al. 2004), which can reinstate 
their antitumor effects (Blank et al. 2004; Iwai et al. 2002; Strome et al. 2003). Current data 
indicate that there is a correlation between the degree of PD-L1 expression and the vertical 
growth of primary tumors in melanoma (Hino et al. 2010). Multivariate analysis 
demonstrated that PD-L1 expression is an independent prognostic factor for melanoma 
(Hino et al. 2010). Therefore, blockade of PD-1: PD-L1 interaction represents a rational 
strategy for cancer immunotherapy.   
MDX-1106 (BMS-936558/ONO-4538) is a fully human immunoglobulin G4 (IgG4) mAb 
specific for PD-1. The drug binds PD-1 with high affinity and blocks its interaction with both 
PD-L1 and PD-L2. A phase I study of single agent MDX-1106 in refractory solid tumors was 
conducted in 39 patients with advanced metastatic non-small cell lung carcinoma (NSCLC), 
melanoma, castrate-resistant prostate cancer, renal cell carcinoma (RCC), or colorectal 
carcinoma (CRC). Although efficacy was not the primary endpoint of this phase I study, of 
the 39 treated patients, 1 durable complete response (CRC) and 2 partial responses 
(melanoma, RCC) were seen. Two additional patients (melanoma, NSCLC) had significant 
lesional tumor regressions, which did not meet criteria for PR.  This study suggested a more 
benign immune-related toxicity profile for anti-PD-1 mAb than one seen associated with 
anti-CTLA-4 mAb. Only 1 patient with metastatic ocular melanoma developed grade 3 
inflammatory colitis following five doses (1 mg/kg) administered over 8 months, which 
responded to steroids and infliximab, while grade 2 immune related adverse events 
occurred in 3 patients presenting with polyarticular arthropathies requiring oral steroids 
and hypothyroidism requiring hormone replacement. (Brahmer et al. 2010).  Another phase 
I trial was conducted on 16 patients with metastatic disease including melanoma.    
Objective responses were documented in 37.5% of patients lasting 3-13+ months; half of the 
patients had melanoma and there were few irAEs (Sznol 2010).   
2.3 Adoptive cell therapy 
The transfer of tumor specific T cells has emerged as a promising therapeutic strategy for 
melanoma. Adoptive cell therapy (ACT) was pioneered at the Surgery Branch of the 
National Cancer Institute (NCI; Bethesda, MD), and to date, has shown some of the most 
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impressive response rates (up to 72%) in patients with metastatic melanoma. The most 
developed approach is based on the ex vivo selection of highly reactive, tumor-infiltrating 
lymphocytes (TIL), their activation and numerical expansion before reinfusion to the 
autologous tumor-bearing host (Dudley et al. 2005). Adoptive transfer after a 
nonmyeloablative conditioning regimen was shown to result in the persistent clonal 
repopulation of T-cells in patients with metastatic melanoma, with the transferred cells 
proliferating in vivo, displaying functional activity, and trafficking to tumor sites (Dudley et 
al. 2002).   
By eliminating competition for endogenous serum cytokines, lymphodepletion may affect 
survival and proliferation of the adoptively transferred TIL.  Data from animal models 
suggested that increased levels of lymphodepletion could improve ACT efficacy.  In murine 
models, lymphodepletion seemed to enhance the antitumor effects of transferred T cells in 
vivo by several mechanisms including the elimination of suppressive CD4+, CD25+ T-
regulatory lymphocytes, the elimination of cellular “sinks” for homeostatic cytokines such 
as IL-7 and IL-15, and the engagement of toll-like receptors on antigen-presenting cells after 
damage to the integrity of the gut epithelial lining (Antony et al. 2005; Gattinoni et al. 2005; 
Paulos et al. 2007).  Cyclophosphamide and fludarabine have been employed for 
nonmyeloablative lymphodepletion.  In a series of 35 patients, Dudley et al. showed that 
adoptive transfer of autologous TIL after nonmyeloablative but lymphodepleting 
chemotherapy with cyclophosphamide and fludarabine followed by high dose IL-2 resulted 
in objective responses in 51% of heavily pretreated patients with metastatic melanoma 
(Dudley et al. 2005).  Further increasing intensity of host preparative lymphodepletion by 
adding total-body irradiation (TBI) of either 2 or 12 Gy prior to cell transfer in 
cyclophosphamide and fludarabine lymphodeleted patients was shown to generate 
response rates up to 52% and 72%, respectively.  Of the 25 patients studied in the 12 Gy TBI 
arm, there were 4 complete responders and at least 2 substantial partial responders (Dudley 
et al. 2008). 
The caveat of adoptive cell therapy is its complexity of several critical preparative steps that 
are both labor intensive and costly which may be the major obstacle to the widespread 
application of this approach. Up to 4 to 6 weeks of cell culture are required to obtain 
adequate numbers of reactive lymphocytes for adoptive transfer. Additionally, much akin to 
the limitation of high dose IL-2, only patients with an excellent functional status are be able 
to withstand the intensity of adoptive cell therapy which may also involve TBI in addition to 
IL-2. On the other hand, as the data from the NCI suggest, such potent therapy in highly 
selected patients does have the potential to induce durable responses and a potential cure.  
To date, however, only small phase II clinical trials have been completed and no phase III 
study has been initiated.  Meanwhile, further innovations beyond current TIL technology 
are underway.   Current strategies seek to improve the yield of TIL cultures, to use vaccines 
to stimulate the transferred T cells in vivo, and to employ gene therapy using genetically 
engineered lymphocytes that express highly reactive T-cell receptors (TCRs) with specific 
anti-melanoma differentiation antigen activity (gp-100 or MART-1), produce IL-2 or other 
molecules promoting an effective immune response. The gene therapy approach is of 
particular interest because the anti-tumor effector T cells could be rapidly expanded for 
adoptive transfer.  Furthermore, it could be of tremendous benefit to patients who do not 
have autologous reactive TIL available and would otherwise be ineligible for adoptive 
immunotherapy (Johnson et al. 2009; Yang et al. 2010). The objective response rates in trials 
employing gene therapy have been reported to be 20% to 45%, and durable tumor 
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regression at all disease sites including the brain has also been observed (Johnson et al. 2009; 
Morgan et al. 2006; Robbins et al. 2011).  
3. Agents targeting oncogenic signaling pathways  
The MAPK pathway (figure 3) has been of keen interest in melanoma in particular since 
Davies et al. first reported that 66% of melanomas harbor activating somatic missense 
mutations in the BRAF gene (V600E), leading to constitutive activation of this pathway 
(Davies et al. 2002; Meier et al. 2005).  The RAF/MEK/ERK pathway  is an important 
regulator of growth, survival and migration and it is constitutively activated in many 
human cancers (Fecher et al. 2008). Physiologically, the RAF/MEK/ERK  signaling pathway 
is activated upon binding of extracellular ligands to growth factor receptors with intrinsic  
tyrosine kinase activity such as epidermal growth factor receptor (EGFR), c-Kit, platelet-
derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor  
 
 
Fig. 3. Molecular targets in melanoma: the MAPK and PI3K pathways.  Binding of growth 
factors to cell surface receptors induces their dimerization and activation of the MAPK 
tyrosine kinase cascade, which includes RAS RAF, MEK and ERK. Activated 
(phosphorylated) ERK translocates into the nucleus, and phosphorylates transcription 
factors for genes involved in cell growth and proliferation. This pathway is constitutively 
activated in many human melanomas. An alternate pathway via PI3K, AKT, and mTOR is 
also activated in some melanomas. 
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(VEGFR), and fibroblast growth factor receptor (FGFR). Signaling through the 
RAF/MEK/ERK pathway eventually leads to the transcription of hundreds if not thousands 
of genes related to cellular proliferation, survival, apoptosis, tumor invasion, and motility 
(Fecher et al. 2008; Shields et al. 2007). Another kinase signaling pathway involves  
PI3K/AKT activating mTOR which promotes signaling to the nucleus and activates genes 
involved in cell growth and proliferation (Stahl et al. 2004).  Studies have shown that a high 
proportion of melanomas carry alterations in the PI3K/AKT pathway (PTEN deletion or 
AKT amplification) independent of the BRAFV600E mutation (Haluska et al. 2007; Vivanco 
and Sawyers 2002). These findings reveal a complex, interlinked network of cellular 
signaling pathways that contain several potentially synergistic therapeutic targets for 
metastatic melanoma.   
3.1 RAF 
Sorafenib (Bay 43-9006) was the first RAF inhibitor to enter early clinical trials.  It is a small-
molecule, multi-targeted tyrosine kinase inhibitor that blocks EGFR, c-Kit, Flt-3, PDGF and 
VEGF in addition to BRAF (Adnane et al. 2006; Wilhelm et al. 2004).  Although Sorafenib 
does not have meaningful activity in melanoma as a single agent (Eisen et al. 2006; Ott et al. 
2010), its use in combination with dacarbazine or temozolomide led to superior objective 
responses and progression –free survival compared to historical response rates to these 
agents (Amaravadi et al. 2009).  However, in a phase III randomized trial (E2603) comparing 
carboplatin, paclitaxel and sorafenib versus carboplatin, paclitaxel and placebo in 
chemotherapy-naïve patients, the futility analysis demonstrated no benefit of the three drug 
combination compared to the two drug chemotherapy combination.  In the PRISM study, 
the addition of Sorafenib to the combination of carboplatin and paclitaxel as second-line 
treatment after chemotherapy with dacarbazine or temozolomide failed to improve 
progression-free survival, response rate and time-to-disease progression in metastatic 
melanoma patients (Hauschild et al. 2009). 
Since then, second generation selective RAF inhibitors have been developed and are actively 
tested in various clinical trials. RG7204 (Roche Pharmaceuticals, formerly PLX4032, 
Plexxikon) is an oral, highly selective inhibitor of the oncogenic V600E mutant BRAF kinase, 
which showed promising results in early clinical studies. In a dose-finding phase I trial, 
11/16 (68%) of patients with mutant BRAF metastatic melanoma achieved PR and four 
patients had minor responses leading to a PFS of 8-9 months (Flaherty 2009).  A dose 
extension phase I trial with 32 patients demonstrated an objective response rate of 81% (2 
CRs, 24 PRs) (Flaherty et al. 2010).  The median PFS among these patients was more than 7 
months.  RG7204 is generally well tolerated with rash, photosensitivity, arthralgia and 
nausea. Of note, 31% of patients developed grade 3 squamous cell carcinoma (SCC), 
keratoacanthoma (KA) type.  The median time to the appearance of a cutaneous 
squamous cell carcinoma was 8 weeks with no reported involvement of other organs.  
Treatment with RG7204 was not interrupted by the appearance of these skin lesions and 
the majority of them were resected (Flaherty et al. 2010).  On the basis of these promising 
results, a phase II trial (BRIM 2) is now fully accrued and a phase III trial (BRIM 3) met its 
primary end points with RG7204 improving both PFS and OS (Chapman, PB, N Engl J 
Med. 2011 Jun 30;364(26):2507-16. Epub 2011 Jun 5) comparing RG7204 to dacarbazine in 
untreated patients with BRAF V600E mutant metastatic melanoma.  
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GSK 2118436 is another oral, highly potent and selective inhibitor of the V600E/K/D mutant 
BRAF.  In a phase I/II study, treatment with GSK 2118436 led  to a decrease in FDG-PET 
metabolic uptake with 11/14 (79%) of melanoma patients showing a decrease from baseline 
(range -5 to -100%), and 18/ 30 (60%) patients demonstrated a > 20% tumor decrease by 
RECIST at first restaging (8-9 wks).  GSK 2118436 showed good tolerability and low grade 
nausea, vomiting, fatigue, headaches and skin changes (including low grade SCC) were the 
main adverse effects (Kefford 2010). A phase II study of GSK2118436 as salvage therapy 
(NCT01153763), and a phase III study of GSK2118436 versus dacarbazine (NCT01227889) as 
front line therapy for mutant BRAF metastatic melanoma patients are underway.   
Judging from the data available to date and the experience in our center, selective RAF 
inhibitors are relatively well tolerated, high grade adverse events are uncommon. Unique 
side effects associated with these novel drugs are the emergence of KA and SCC. These 
lesions can appear as early as 2 weeks after the initiation of therapy and are reported in 15–
30% of the patients (Arnault et al. 2009; Flaherty et al. 2010).  Histologically, KA is almost 
indistinguishable from a well differentiated SCC.  In contrast to KA, SCC is a malignant 
lesion that does not regress spontaneously and has the potential for metastasis.  The biologic 
mechanism and natural history of these lesions in the context of RAF inhibitors, in 
comparison to their spontaneous counterparts, are currently unknown (Arnault et al. 2009; 
Robert et al. 2010).   
3.2 MEK 
The serine/threonine tyrosine kinase MEK acts downstream from RAF in the 
RAF/MEK/ERK pathway; its inhibition is an attractive anticancer strategy as it has the 
potential to block upregulated signal transduction through this pathway, regardless of the 
upstream position of the oncogenic aberration.  AZD6244 (ARRY-142886, Array BioPharma, 
AstraZeneca) is a selective MEK1/2 inhibitor that has shown preclinical activity (Yeh et al. 
2007) and demonstrated clinical activity in a phase I study with a relatively benign toxicity 
profile (Adjei et al. 2008). These results led to a randomized phase II trial comparing 
AZD6244 versus temozolomide in chemotherapy naïve advanced melanoma patients 
(Dummer 2008). A total of 200 patients were enrolled with 104 and 96 patients randomized 
to AZD6244 and temozolomide, respectively; those who progressed on temozolomide could 
crossover to AZD6244.  Results showed a trend toward OS in patients with BRAF mutations 
in the AZD6244 arm (Dummer 2008).  At the 2010 ASCO annual meeting, the early results of 
a phase I study with AZD6244 in combination with docetaxel, dacarbazine or temsirolimus 
suggests the presence of BRAF mutation was significantly associated with clinical responses 
and increased time to progression. (Patel 2010). Several phase II studies of AZD6244 are 
underway for advanced melanoma patients with BRAF mutations as front line therapy:  for 
treatment-naïve patients versus temozolomide (NCT00338130), in combination with 
dacarbazine versus dacarbazine alone (NCT00936221), as well as salvage therapy 
(NCT00866177). GSK1120212 is another potent and selective inhibitor of the MEK1/2 
enzymes with promising anti-tumor activity in a phase I clinical trial, resulting in response 
rate > 70%  in advanced melanoma patients with known BRAF mutations, including one 
patient who was previously treated with PLX4032 (Infante 2010). This drug is currently 
investigated in phase II and III clinical trials for advanced BRAF mutant melanoma patients 
who were either previously treated with a BRAF inhibitor or not. (NCT01245062, 
NCT01037127).  
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Although targeting the MAPK pathway is a promising new therapeutic approach for the 
treatment of melanoma, and treatment with selective BRAF and MEK inhibitors can induce 
high response rates, the limited duration of these responses in most patients, most likely  
because of emerging resistance to these inhibitors represents a significant clinical challenge.  
Molecular redundancy, in part due to the existence of RAF isoforms and signaling through 
alternative oncogenic pathways, such as PI3K/AKT/mTOR pathway (Jiang et al. 2011; 
Paraiso et al. 2010), receptor tyrosine kinase (PDGFRβ)-dependent pathway (Nazarian et al. 
2010) and COT (MAP3K8) (Johannessen et al. 2010), may provide the melanoma cells’ 
escape mechanisms to specific pathway inhibitors and underscore their ability to adapt to 
pharmacological challenges (Jiang et al. 2011; Paraiso et al. 2010).  In preclinical models, it 
has been reported that acquired resistance of melanoma cells to the BRAF inhibitors was 
associated with rebound activation of the RAF/MEK/ERK pathway (Paraiso et al. 2010).  In 
line with this finding, activating signals to downstream MEK/ERK has been shown to 
switch to ARAF (Villanueva et al. 2010) or CRAF (Montagut et al. 2008; Villanueva et al. 
2010) via N-RAS upregulation (Nazarian et al. 2010) to overcome the effect of BRAF 
inhibition.  Moreover, the majority of melanoma cells harboring the BRAF V600E mutation 
retained the wild-type BRAF allele which could be rescued from the effects of BRAF knock-
down by extracellular growth factors such as basic fibroblast growth factor, hepatocyte 
growth factor or endothelin-1 (Christensen and Guldberg 2005).   
3.3 C-Kit 
Imatinib is a selective tyrosine kinase inhibitor with multiple targets, including c-Kit and 
PDGR receptors, and has shown to be highly efficacious in chronic myelogenous leukemia and 
GIST tumors (Heinrich et al. 2000).  Initial phase II trials with this agent in melanoma were 
disappointing with no objective responses (Ugurel et al. 2005; Wyman et al. 2006).  However, 
gain of function mutations, gene amplifications and over-expression of c-kit were 
subsequently reported in 30-40% of mucosal, acral and cutaneous melanomas with chronic sun 
damage (Curtin et al. 2006).  Impressive tumor regression was documented in a patient with 
mucosal melanoma who carried a mutation in the juxtamembranous domain of c-Kit (exon 11) 
in response to single agent imatinib (Hodi et al. 2008a). Moreover, preclinical studies showed 
sensitivity of c-Kit mutant mucosal melanoma, providing a rationale for the use of imatinib in 
this melanoma type.  Preliminary results of a phase II trial evaluating the effect of imatinib in 
patients with metastatic melanoma with c-kit aberrations were presented at ASCO 2009.  Over 
30% of patients achieved a response (complete and partial response), whereas 50% had disease 
stability (Carvajal 2009).  Another phase I/II study to define safety and efficacy of imatinib in 
combination with temozolomide in patients with unresectable, stage III/IV melanoma is 
currently underway. After the data on c-kit alterations became available when the trial was 
already in progress, patients with mucosal, acral and chronic sun damage melanomas were 
preferentially enrolled in the phase II part of the study. Early results of the trial were presented 
at ASCO 2008 (Fecher 2008).  Of the 23 patients treated, 16 had been enrolled in phase I and 7 
in phase II.  The combination was well tolerated and demonstrated anti-tumor activity in 
melanoma.  Of the 7 patients treated in the phase II trial, 1 patient had a CR and 6 had PRs 
(Fecher 2008).  Phase II studies with a second generation c-kit inhibitor (nilotinib) in first or 
second line therapies for advanced melanoma with c-Kit mutation or amplification are 
ongoing (NCT01168050, NCT01099514). In addition, the multi-targeted receptor tyrosine 
kinase inhibitor sunitinib has shown potential efficacy in patients with c-kit mutated 
melanoma in an early phase clinical trial (Minor 2010).   
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3.4 MTOR 
Resistance of mutant BRAF melanoma cells to RAF/MEK inhibition may also be due to 
activation of other survival signaling pathways such as the PI3K/AKT/mTOR pathway 
(figure 3) resulting in melanoma development and progression (Shao and Aplin 2010; Stahl 
et al. 2004; Villanueva et al. 2010).  Recent reports suggested a significant correlation of 
increased PI3K-AKT activity with resistance to RAF/MEK inhibitors in melanoma (Gopal et 
al. 2010; Villanueva et al. 2010) and that inhibition of the PI3K/AKT/mTOR pathway could 
suppress MEK inhibitor-induced activation of AKT and resulted in synergistic cell killing 
with a MEK inhibitor (AZD6244) (Gopal et al. 2010).  This provides a rationale for 
combinatorial therapy leading to dual inhibition of both RAF/MEK/ERK and 
PI3K/AKT/mTOR pathways.  A phase II trial of the mTOR inhibitor temsirolimus (CCI-
779) combined with the MEK inhibitor AZD6244 is currently recruiting treatment-naïve 
patients with BRAF mutant advanced melanoma (NCT01166126).  In addition, inhibition of 
the PI3K/AKT/mTOR signaling pathway was found to sensitize melanoma cells to 
chemotherapeutic agents such as cisplatin and temozolomide in vitro as evidenced by 
enhanced apoptosis and suppressed invasive tumor growth (Sinnberg et al. 2009).  A Phase 
II study of the mTOR inhibitor everolimus in combination with paclitaxel and carboplatin in 
patients with metastatic melanoma is in progress (NCT01014351).   
4. Other targeted drugs currently in clinical development 
4.1 PARP Inhibitors 
Poly-ADP ribose polymerase (PARP) is a key enzyme in DNA repair.  ADP- ribosylation is 
involved in DNA excision repair and  inhibition of the enzyme enhances the cytotoxicity of 
DNA damaging agents (Durkacz et al. 1980). PARP inhibition in BRCA-deficient breast 
cancers has shown a favorable therapeutic index.  In a phase II trial, olaparib, a novel poly-
ADP ribose polymerase (PARP) inhibitor, achieved an objective response rate of 41% in 
women with BRCA1 or BRCA2 mutations and advanced breast cancer (Tutt et al. 2010).  In 
melanoma, PARP-1 expression has been shown to correlate with tumor thickness (Staibano 
et al. 2005), a poor prognostic factor for melanoma, and over-expression of PARP-1 is 
correlated with recurrence and/or progression of the disease (Csete et al. 2009), suggesting 
that it potentially is as a promising new therapeutic target.  AG014699 is the first PARP 
inhibitor to enter a clinical trial and was studied in combination with temozolomide in a 
phase II study with 40 chemotherapy-naïve metastatic melanoma patients.  Of the 20 
evaluable patients, there were 4 confirmed PRs and 4 SDs (Plummer 2006).   
4.2 Antibody-drug conjugate 
Glycoprotein NMB (GPNMB) is over-expressed in a variety of cancers including melanoma. 
CR011-vcMMAE is an antibody-drug conjugate comprised of a fully-human monoclonal 
antibody directed at the extracellular domain of GPNMB linked to a potent tubulin 
destabilizing agent, monomethyl auristatin E (MMAE). The enzyme-sensitive linker is 
designed to be stable in the bloodstream and to release MMAE inside tumor cells, resulting 
in cancer cell death. A phase I/II study of CR011-vcMMAE in patients with advanced, 
pretreated melanoma has completed accrual (NCT00412828).  At the ASCO annual meeting 
in  2010,  CR-vcMMAE at 1.88mg/kg, when given every three weeks, was reported to 
produce an objective response rate of 15% (Hamid 2010). 
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4.3 Antibodies against integrins 
Integrins of the αv family, such as αvβ3 and αvβ5, are implicated in tumor-induced 
angiogenesis and are thought to play a role in tumor growth.  CNTO 95 is a fully human 
monoclonal antibody directed against αv Integrins, which has demonstrated anti-tumor and 
anti-angiogenic activities in animal models (Trikha et al. 2004).  Results of a phase I study to 
assess safety and pharmacokinetics of CNTO 95 in patients with advanced refractory solid 
tumors demonstrated good tolerability (Jayson 2004).  A phase I/II multicenter, randomized 
and double-blind study to assess the safety and efficacy of CNTO 95, alone and in 
combination with dacarbazine, in stage IV melanoma patients has been completed and 
result pending publication (NCT00246012).  Another phase I trial of CNTO 95 in patients 
with metastatic melanoma and angiosarcoma recently demonstrated a manageable toxicity 
profile, and encouragingly, 2 of 18 patients with melanoma, who had failed several 
therapeutic regimens, sustained stable disease 5 and 7 months, respectively (O'Day et al. 
2011). 
5. Conclusion 
Understanding the molecular biology of melanoma and unraveling of several signaling 
pathways over the last few years, as well as advances in immunology have led to the 
development of a number of promising novel therapeutic treatment options for metastatic 
melanoma.  Immune-checkpoint blockade with ipilimumab has demonstrated increased 
overall survival in a randomized phase III clinical study (Hodi et al. 2010).  Other immune-
related approaches, such as anti-PD1/PD-L1 and adoptive cell therapy, are on the horizon.  
The identification of the BRAF V600E mutation led to the development of new agents that 
specifically block the MAPK pathway.  Improved PFS and OS as a result of treatment with 
the V600E mutant BRAF kinase inhibitor RG7204 in BRIM 3 have been reported.  
Encouraging response rates with imatinib therapy in patients with mucosal, acral, and sun-
damaged skin melanomas that harbor mutations or amplification in the c-kit gene have also 
been documented.  These results herald the era of individualized therapies based on specific 
tumor genotypes, of which scientifically thoughtful combinations will usher in a new 
standard of care for metastatic melanoma in the near future.   
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Surgery continues to be the mainstay treatment for melanoma localized to the primary tumor and/or lymph
nodes. Results from randomized controlled trials indicate that sentinel node biopsy for the treatment of
cutaneous melanoma of intermediate thickness has a beneficial effect on recurrence rates, and adjuvant
radiotherapy to regional lymph node fields following surgical resection reduces loco-regional recurrence in
patients at high risk of relapse. Isolated limb perfusion, electrochemotherapy, and photodynamic therapy
continue to be evaluated for treatment of stage IV disease. However, the greatest excitement in new treatment
has been with targeted therapies for genetic mutations. In particular, the promising results of partial and
complete tumor response in stage IV disease from early phase trials of the B-RAF kinase inhibitors. This book
provides a contemporary insight into the therapeutic treatment options for patients with metastatic melanoma
and is relevant to clinicians and researchers worldwide. In addition, an update on current clinical trials for
melanoma treatment has been included, and two chapters have been reserved to discuss the treatment of oral
and uveal melanoma.
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